Novo, Lilly tout respective early response and weight loss maintenance data as GLP-1 rivalry intensifies

Eli Lilly and Novo Nordisk are building cases for their incretin drugs both new and old as attractive weight loss maintenance options and a potentially speedier option to shed pounds, respectively. Eli Lilly and Novo Nordisk are building cases for their incretin drugs both new and old as attractive weight loss maintenance options and a potentially speedier option to shed pounds, respectively. Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Special Report Awards Gala Trending Oncology Supply Chain AI and Machine Learning Awards Outsourcing Awards Innovation Awards…

Source: FiercePharma